We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App





Coronavirus Immunity in COVID-19 Patients May Not Last More Than Two Months, Finds New Study

By HospiMedica International staff writers
Posted on 23 Jun 2020
Initial results from an antibody testing study have revealed that COVID-19 antibodies remain stable in the blood of the majority of infected individuals almost two months after diagnosis and possibly longer.

However, the study, led by researchers and clinicians at St George’s, University of London (London, UK) in collaboration with colleagues from other institutions, did not detect antibodies in everyone exposed to the virus, thus opening discussions on how best to interpret antibody and viral tests. More...
These findings answer questions on how long people can remain immune after exposure to COVID-19 and provide insights into how different age and ethnic groups respond to infection.

In the study, the researchers analyzed antibody test results from 177 individuals diagnosed with COVID-19 infection from a viral test and measured the levels of COVID-19 antibodies in their blood. The results showed that in patients with an antibody response, the levels remained stable for the duration of the study (almost two months). The study also showed that those patients with the most severe infections having the largest inflammatory response were more likely to develop antibodies. The researchers have attributed this to antibody responses working in parallel with an inflammatory response to severe disease, or that a higher viral load could lead to greater stimulation of the inflammatory and antibody development pathways.

Between 2 and 8.5% of patients did not develop COVID-19 antibodies at all which, according to the researchers, may be due to the fact that the immune response in these patients could be through other immune response mechanisms, such as different antigens or T-cells. Another reason could be that relatively mild infections may be restricted to particular locations in the body, such as within mucosal cells of the respiratory tract, where antibody responses are instead dominated by a secretory immune system. The study also found that being of non-white ethnicity was associated with a higher antibody response, just as older patients and those with other conditions, such as with hypertension and being overweight were also more likely to have an antibody response.

“Our results provide an improved understanding of how best to use viral and antibody tests for coronavirus, especially when not every person exposed to the virus will have a positive response. We need to understand how best to interpret the results from these tests to control the spread of the virus, as well as identifying those who may be immune to the disease,” said Professor Sanjeev Krishna, corresponding author on the paper from St George’s, University of London.

“With the number of infections in the UK going down, we now have the very welcome challenge of attempting to carry out more tests to understand whether other factors are associated with an immune response, such as viral load and genetic factors. We hope that by sharing our data at an early stage, this will accelerate progress towards effective use of test results around the world.”

Related Links:
St George’s, University of London


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Lateral Lumbar Interbody Spacer
CALIBER-L
New
High-Precision QA Tool
DEXA Phantom
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Surgical Techniques

view channel
Image: The milli-spinner can shrink blood clots without rupturing them (Photo courtesy of Andrew Brodhead/Stanford)

New Technology More Than Doubles Success Rate for Blood Clot Removal

In cases of ischemic stroke, where a blood clot obstructs oxygen supply to the brain, time is critical. The faster the clot is removed and blood flow restored, the more brain tissue can be saved, improving... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.